Condition: Lung Cancer · Stage IIIA-cN2 · Operated With Curative Intent · Sponsor: Assistance Publique - Hôpitaux de Paris
Mediastinal lymph node (LN) involvement (N2) in non-small cell lung cancer (NSCLC) concerns 15% of resectable tumors and is associated with a poor prognosis and an overall survival reaching 9 to 49%. Literature fails to provide any definitive consensus regarding the management of these patients, except for the platinum-based doublet chemotherapy. The N2 involvement remains a matter of debate because of its not yet well-classified heterogeneity. Regarding anatomy, the Mountain and Dresler's regional LN classification for lung cancer staging remains the reference. Different studies classified IIIA-N2 disease into 4 groups, in addition to the skip-N2 phenomenon: minimal-N2, N2 single station, N2 multiple stations, and bulky-N2. Other subgroups were recently proposed for the 8th edition of the TNM: N2a1 - single station skip, N2a2 - single station non-skip, N2b - multiple stations. The French National Cancer Institute (INCa) proposed guidelines, but in case of cN2 staging without mediastinal infiltration, guidelines remained imprecise ("resectability should be discussed for each case") and suggested surgery first, or induction chemotherapy, or concomitant chemoradiation. Thus, optimal management of cIIIA-N2 remains controversial but complete tumor resection can be related to long-term survival in some patients, including 10 years after surgery \[1\]. In this situation, the identification of markers that will help select IIIA-N2 patients who will benefit from surgical resection …
This description comes directly from the study's public registry record.
Antoine LEGRAS, MD PhD · 33 2 47474747 · antlegras@gmail.com
Liliane HAMMANI-BERKANI, MSc · 33 156093762 · liliane.berkani@aphp.fr
Always discuss trial participation with your own doctor first.
| Hôpital du Haut-Lévêque, CHU de Bordeaux | Bordeaux, France | Not Yet Recruiting |
| Hôpital Militaire Percy | Clamart, France | Not Yet Recruiting |
| Hôpital Nord | Marseille, France | Not Yet Recruiting |
| Hôpital Pasteur, CHU de Nice | Nice, France | Not Yet Recruiting |
| Hegp-Aphp | Paris, France | Active Not Recruiting |
| Hôpital Européen Georges-Pompidou | Paris, France | Recruiting |
| Hôpital Bichat | Paris, France | Not Yet Recruiting |
| Hôpital Cochin | Paris, France | Not Yet Recruiting |
| Hôpital Pontchaillou, CHU de Rennes | Rennes, France | Not Yet Recruiting |
| Hôpitaux universitaires de Strasbourg | Strasbourg, France | Not Yet Recruiting |
| Hôpital Larrey, CHU de Toulouse | Toulouse, France | Not Yet Recruiting |
| CHRU de Tours | Tours, France | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04677205